{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:26:47Z","timestamp":1784647607951,"version":"3.55.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sipuleucel-T, the first therapeutic cancer vaccine approved by the U.S. Food and Drug Administration (FDA), represents a crucial treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, the characteristics of cardiovascular adverse events (CVAEs) associated with sipuleucel-T remain poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, pharmacovigilance analysis used case safety reports from the FDA Adverse Event Reporting System (FAERS) spanning April 2010 to March 2025. Reporting odds ratio (ROR) and information component (IC) were applied to identify and evaluate potential CVAEs associated with sipuleucel-T. Kaplan\u2013Meier method and Weibull distribution were used to analyze reported time-to-onset patterns of sipuleucel-T-related CVAEs. Multivariate logistic regression was employed to explore risk factors for CVAEs following sipuleucel-T treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 4,797 sipuleucel-T-related reports, 743 (15.49%) documented CVAEs, of which 427 (57.5%) were classified as serious. Positive CVAE signals associated with sipuleucel-T included hypertension, venous thromboembolic events, arterial thromboembolic events, cardiac failure, cardiac arrhythmias, and myocardial infarction. The median time to onset of sipuleucel-T-related CVAEs was 14 days, with 80.11% occurring within 1 month. Moreover, the median time to onset of fatal CVAEs was significantly later than that of non-fatal CVAEs (22 days\n                      <jats:italic>vs.<\/jats:italic>\n                      14 days;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0076). Additionally, age \u2265 75 years, body weight \u2265 75 kg, and concomitant use of \u22655 medications were identified as independent risk factors for sipuleucel-T-related CVAEs (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study characterizes the clinical spectrum, time-to-onset patterns, and risk factors of sipuleucel-T-associated CVAEs, providing essential pharmacovigilance data for managing patients with mCRPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1716090","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:33:34Z","timestamp":1768890814000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling the hidden cardiovascular risk of sipuleucel-T: a pharmacovigilance analysis using the FDA Adverse Event Reporting System, 2010\u20132025"],"prefix":"10.3389","volume":"16","author":[{"given":"Wensheng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]},{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fudan University Shanghai Cancer Center Xiamen Hospital","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00167-5","article-title":"Metastatic prostate cancer management: 20 years of progress","volume":"24","author":"Gravis","year":"2023","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251347857","article-title":"Immunotherapy in metastatic prostate cancer","volume":"17","author":"Dwyer","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01215-2","article-title":"Metastatic castration-resistant prostate cancer: advances in treatment and symptom management","volume":"25","author":"Kulasegaran","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3223","article-title":"Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer","volume":"17","author":"Beer","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B8","article-title":"Sipuleucel-T for the treatment of patients with metastatic castrate-resistant prostate cancer: considerations for clinical practice","volume":"17","author":"Pieczonka","year":"2015","journal-title":"Rev Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13400","article-title":"Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database","volume":"8","author":"Moey","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1558128","article-title":"Emerging cardiovascular toxicity associated with CDK4\/6 inhibitors: real-world insights from the FDA adverse event reporting system","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for drUg safety signal detection using individual case safety reports in pharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.70389\/PJS.100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0665-5","article-title":"Causality assessment of olfactory and gustatory dysfunction associated with intranasal fluticasone propionate: application of the bradford hill criteria","volume":"35","author":"Muganurmath","year":"2018","journal-title":"Adv Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2920","article-title":"Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: A pharmacovigilance study based on the FAERS database","volume":"114","author":"Xia","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.09.019","article-title":"Unraveling the spectrum of ocular toxicity with oxaliplatin: clinical feature analysis of cases and pharmacovigilance assessment of the US food and drug administration adverse event reporting system database","volume":"46","author":"Liu","year":"2024","journal-title":"Clin Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1646038","article-title":"Emerging causes of anticancer therapies-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121384","article-title":"Vaccine therapies for prostate cancer: current status and future outlook","volume":"12","author":"Zhou","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e199249","DOI":"10.1001\/jamanetworkopen.2019.9249","article-title":"Adverse events associated with the use of sipuleucel-T reported to the US food and drug administration\u2019s adverse event reporting system, 2010-2017","volume":"2","author":"Dores","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32786","article-title":"Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data","volume":"126","author":"Dores","year":"2020","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002931","article-title":"Pharmacovigilance insights into drug-associated venous thromboembolism","volume":"111","author":"Cai","year":"2025","journal-title":"Int J Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01130-y","article-title":"Update on immunotherapy cardiotoxicity: checkpoint inhibitors, CAR T, and beyond","volume":"24","author":"Patel","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e053698","DOI":"10.1136\/bmjopen-2021-053698","article-title":"Impacts of type 2 diabetes mellitus and hypertension on the incidence of cardiovascular diseases and stroke in China real-world setting: a retrospective cohort study","volume":"11","author":"Liu","year":"2021","journal-title":"BMJ Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"Mahajan","year":"2022","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2025.02.011","article-title":"Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patients","volume":"104","author":"Cebe","year":"2025","journal-title":"Adv Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.eururo.2015.06.022","article-title":"Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism","volume":"70","author":"Klil-Drori","year":"2016","journal-title":"Eur Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00832-0","article-title":"Cardiovascular risk in ADT recipients: does the type of ADT matter","volume":"27","author":"Pinthus","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1317-2","article-title":"Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer","volume":"62","author":"Sheikh","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1056417","article-title":"Evaluating immune responses after sipuleucel-T therapy","volume":"16","author":"Strauss","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.124.048137","article-title":"Immunothrombosis in acute ischemic stroke","volume":"56","author":"Wang","year":"2025","journal-title":"Stroke"},{"key":"B34","first-page":"1","article-title":"Dendritic cell immunotherapy of prostate cancer: preclinical models and early clinical experience","volume":"11","author":"Laus","year":"2001","journal-title":"Cancer Res Ther Control"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrurol.2015.33","article-title":"Immunotherapy: Sipuleucel-T induces humoral antigen spread in patients with mCRPC","volume":"12","author":"Sidaway","year":"2015","journal-title":"Nat Rev Urol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.01.001","article-title":"Uncontrolled cardiovascular risk factors in prostate cancer patients: are we leaving too much on the table","volume":"5","author":"Moningi","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050498","article-title":"Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system","volume":"54","author":"Alvarez-Requejo","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002607","article-title":"Immunotherapy-induced cholestasis in cancer: insights from the two real-world pharmacovigilance databases of FAERS and VigiBase","volume":"111","author":"Yan","year":"2025","journal-title":"Int J Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1716090\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:33:35Z","timestamp":1768890815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1716090\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1716090"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1716090","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"article-number":"1716090"}}